Drug
Aln Htt02
Aln Htt02: highest development phase Phase 1, developed by Alnylam Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Alnylam Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALN-HTT02 NCT06585449 | Phase 1 | Huntington's Disease |
Latest
No recent events.
Follow Aln Htt02 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.